Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program—RLYB116, a complement C5 inhibitor designed for once-weekly subcutaneous injection—advancing through clinical trials, and a secondary program targeting iron overload disorders. The company partners with organizations including AbCellera on antibody discovery and has licensed foundational technology from providers of drug discovery platforms and antibody capabilities. Rallybio expects to generate revenue from product sales following regulatory approval and commercialization, as well as from milestone and royalty payments under its licensing and collaboration agreements.